drugset / Trial / NCT01953315

Muscle Progenitor Cell Therapy for Urinary Incontinence

NCT01953315 ↗

Phase 1 Completed 10 enrolled Wake Forest University
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate the safety of muscle progenitor cells (MPCs) for the treatment of urinary incontinence due to incompetent outlet (bladder neck/urethra).

Timeline

Start
2014-01
Primary completion
2018-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Muscle Progenitor Cells Cell therapy — Other